- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05487742
Neuroprotective Effect of Dexomitomidine
Evaluation of Neuroprotective Effect of Dexmedetomidine in Traumatic Brain Injury
Study Overview
Status
Intervention / Treatment
Detailed Description
Assessment will be done for the patients by taking careful medical history for any medical disorder, therapeutic anticoagulant, allergy to chemical compounds or addiction problems, and performing trauma survey check up ( chest x-ray, abdomen US, CT brain for documentation of injury) with general and physical examination for CNS (assessement of GCS) , chest, heart, abdomen and peripheral limbs for any abnormality . Then, routine and relative investigations will be carried out such as complete blood picture, renal and liver function tests, coagulation tests and random blood sugar.
all patients will be monitored with five- lead ECG, non-invasive blood pressure, pulse oximetry and end tidal CO2. Then a 20 gauge IV cannula will be inserted into a peripheral upper extremity vein for drug administration and ( DEX group) patients received 0.5 ug /kg/hr dexmedetomidine continuous infusion for 72 hour. Ephedrine will be administrated to maintain the MAP at the pre-sedation level if BP decrease 20 % from baseline BP and atropine if pulse decrease below 50 b/m . No extra sedatives, other vasoactive drugs or volume resuscitation will be used during sedation. Patient demographics, including age, sex, weight, primary diagnosis, Acute Physiology and Chronic Health Evaluation (APACHE) II score and postresuscitation Glasgow Coma Scale (GCS) score will be collected. CBF will be measured at pre-sedation and after cessation of sedation (dexmedetomidine administration). The CMRe and CMRe/CBF will also be calculated. Measurements of blood gas analysis and haemodynamic parameters [systolic blood pressure (SBP), diastolic blood pressure (DBP), MAP and heart rate (HR)] will be collected at pre-sedation and after cessation of sedation (dexmedetomidine administration).
CBF measurement :
CBF will be evaluated in the extra-cranial internal carotid artery (ICA) and vertebral artery (VA) using a spectral Doppler ultrasound technique . Briefly, the procedure will be performed with the patient in the supine position with a 7.5-MHz linear array transducer of a colour coded ultrasound system . The patients' head will slightly be elevated and turned to the contralateral side at a 25 - 40 angle for ICA measurements and at a 10 angle for VA measurements. ICA will be assessed at the segment located 1.5 cm distal to the carotid bifurcation and VA will be measured between the transverse processes of the C4 and C5 vertebrae.
Blood flow velocities will be obtained by keeping the Doppler insonation angle at a standard 60. Time averaged flow velocity (TAV) will be determined as the integral of the mean flow velocities of all moving particles passing the sample volume over 3-5 complete cardiac cycles. The TAV, peak systolic velocity, end-diastolic velocity and inner vessel diameter (d) will be measured during the bilateral ICA and VA CBF measurements. The intravascular flow volume (FV) of each artery will be calculated by the formula: FV= TAV x (d/2) x ℼ CBF will be calculated as the sum of bilateral ICA and VA flow volumes. All ultrasound examinations will be performed in triplicate by the same radiologist using the same Doppler ultrasonography device.
CBF reduction will be calculated as:
(pre-sedation CBF - during-sedation CBF) / pre-sedation CBF x100.
CMRe evaluation :
An 18-gauge venous catheter (Arrow International Inc., Bernville, PA) will be introduced into the right internal jugular vein at the level of the cricothyroid membrane and passed into the jugular bulb or at the base of the skull in a retrograde fashion with ultrasound guidance, as previously described [12]. Blood samples for jugular venous oxygen saturation (SjvO2) measurements will be collected intermittently by aspiration at a rate of less than 1.5 ml min . Arterial oxygen saturation (SaO2) and partial pressure of carbon dioxide (PaCO2) were assessed in blood samples taken from the femoral artery. The CMRe and oxygen extraction ratio (OER) were calculated as follows:
CMRe = CBFx (SaO2ml_1 _ SjvO2ml_1) (relative units):
OER = (SaO2 _ SjvO2)/SaO2 The CMRe / CBF ratio was also determined at each time point. The reduction in CMRe was calculated using the method described above. 80 Patients will be randomly classified using sealed envelope into two equal groups each of 40 patients Group I (control group): Patients of this group receive placebo infusion for 72 hours. Group II (DEX group): Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Wafaa Abdelwahed
- Phone Number: +201011242278
- Email: wafaaabdelwahed@med.tanta.edu.eg
Study Contact Backup
- Name: Elsayed Negm
- Phone Number: +201143304951
- Email: wafaa.madhy@gmail.com
Study Locations
-
-
-
Tanta, Egypt
- Recruiting
- Faculty of medicine Tanta university
-
Contact:
- wafa Abdelwahed
- Phone Number: +201011242278
- Email: wafaaabdelwahed@med.tanta.edu.eg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
- Patients of either sex
- Age ranged from 18-60 years
- Patients with mild to moderate traumatic brain injury assessed by CT and 8< GCS < 15 -
Exclusion Criteria:
1 - Patient relative refusal. 2-Severe traumatic brain injury GCS < 8 3-prescence of other organ injury. 4-MAP lower than 80 mmHg 5- hepatic or kidney function dysfunction 6-received any vasoactive agents or sedatives or recieve drugs that affect CBF during the experiment 7- Pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group I (control group):
Patients of this group receive placebo infusion for 72 hours.
|
salin infused as aplacebo for 72 hours
|
Active Comparator: Group II (DEX group):
Patients of this group receive 0.5 ug/kg/hr dexmedetomidine continuous infusion for 72 hour
|
dexmedetomidine will be infused for 72 hour in mild and moderate traumatic brain injury patient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change in CBF during sedation.
Time Frame: 6 months
|
cerebral blood flow will be measured whether changed by dexmedetomine infusion or not
|
6 months
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Brain Injuries, Traumatic
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- 35526/6/22
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dexmedetomidine Neuroprotective Effect in Traumatic Brain Injury
-
Tianjin Medical University General HospitalShehzaad Joomye; Haiyun Wang; Donglai YanUnknownThe Intraoperative Effect of Dexmedetomidine on Cisatracurium Infusion Consumption and Its Recovery Index. | Effect of Dexmedetomidine on Sufentanil Consumption. | Quantitative Analysis of Cisatracurium Infusion Requirements, Sufentanil Consumption and Recovery Index in Different Age...China
-
Postgraduate Institute of Medical Education and...UnknownSodium Imbalance in Traumatic Brain InjuryIndia
-
Assistance Publique - Hôpitaux de ParisCompletedPrognosis of Neurological Outcome at 6 Months in Patients Undergoing Traumatic Brain InjuryFrance
-
Fondazione per la Ricerca Ospedale MaggioreCompletedBrain Injuries, Traumatic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateItaly
-
Toronto Rehabilitation InstituteCentre for Aging and Brain Health Innovation; Ontario Neurotrauma FoundationUnknownBrain Injuries, Traumatic | Brain Injury, Chronic | Brain Injury Traumatic Severe | Brain Injury Traumatic ModerateCanada
-
Hospital Sirio-LibanesUniversity of Sao Paulo; Ministry of Health, Brazil; Hospital Sao Rafael; PROAD... and other collaboratorsRecruitingBrain Injury Traumatic Severe | Brain Injury Traumatic Moderate | Post Traumatic EpilepsyBrazil
-
University of TurkuTurku University Hospital; The Finnish Funding Agency for Technology and Innovation... and other collaboratorsCompletedBrain Injuries | TBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Traumatic Brain Injury | Injury, Brain, TraumaticFinland
-
Boston Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...CompletedProtein Feeding in Post-traumatic Injury PatientsUnited States
-
Children's Hospital Medical Center, CincinnatiUniversity of CincinnatiCompletedBrain Injury Traumatic MildUnited States
-
BrainScope Company, Inc.RecruitingTBI (Traumatic Brain Injury) | Concussion, Brain | MTBI - Mild Traumatic Brain Injury | Closed Head InjuryUnited States
Clinical Trials on placebo salin infusion
-
Andalusian Initiative for Advanced Therapies -...Iniciativa Andaluza en Terapias AvanzadasCompletedDiscordant Immunological Response in HIV Infected SubjectsSpain
-
Jozef BartunekKing's College LondonTerminatedAcute Myocardial InfarctionNetherlands, France, Belgium, United Kingdom
-
The University of Texas Health Science Center,...United States Department of Defense; U.S. Army Medical Research and Development...Active, not recruitingTBI (Traumatic Brain Injury) | Brain Injuries, Traumatic | Brain Injuries, AcuteUnited States
-
Sema KoçaşlıCompleted
-
Dompé Farmaceutici S.p.ACompletedKidney Diseases | Ischemia-Reperfusion InjuryUnited States, France, Italy, Spain
-
Novartis PharmaceuticalsCompletedPigmented Villonodular Synovitis | PVNS | Giant Cell Tumor of the Tendon Sheath | GCCTS | Tenosynovial Giant Cell Tumor Localized or Diffused Type | GCTSUnited States, Switzerland
-
Universitätsklinikum Hamburg-EppendorfCharite University, Berlin, Germany; Deutsches Zentrum für Herz-Kreislauf-Forschung...RecruitingIron Deficiency | Systolic Heart FailureGermany, Hungary, Italy, Poland, Portugal, Serbia, Slovenia, Spain
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom